Please login to the form below
19
Revenue 2017Celgene
The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Celgene's 2013 oncology sales performance.
Amgen reports positive results for inflammatory disease drug Otezla in psoriatic arthritis
Amgen bought Otezla from Celgene Corporation in 2019 for $13.4bn to strengthen its inflammation portfolio.
Testimonials
society alike – values which Celgene strive to achieve. ... Lisa McCurdy, Associate Director - Haematology, Celgene. “You never forget that feeling of being a winner and of knowing that you are at the very top of your profession – it means that
FDA approves Amgen’s Otezla for all patients with plaque psoriasis
Celgene’s top psoriasis drug, Otezla (apremilast), which was raking in $1.6bn a year and growing fast, clashed with one of BMS' most promising molecules, deucravacitinib. ... As it became clear that anti-competition regulators would balk at BMS owning
Merck to acquire Acceleron in a deal worth around $11.5bn
The drug is part of a long-standing global collaboration with Celgene, now part of Bristol Myers Squibb (BMS).
Mysterious big pharma company eyes US biotech Acceleron
The drug is part of a long-standing global collaboration with Celgene, now part of Bristol Myers Squibb (BMS).
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
Subscribe to our email news alerts
- New Playbook Alert: Virtual Patient Engagement
- AbbVie to expand solid tumour portfolio with $10bn ImmunoGen acquisition
- UK Biobank reveals new data from world's largest genetic project
- New study finds dose of Mavenclad treatment could predict MS relapse risk
- Astellas shares positive 24-week results for non-hormonal menopause drug fezolinetant
- GSK global survey reveals misunderstandings about shingles in adults
No results were found
PMHub
Genetic Digital
We guide healthcare and life sciences organisations through digital transformation. Simplifying the complex world of tech and marketing, we create...
Latest intelligence
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
